HEM.V · Hemostemix Inc

-

Please sign in to comment on HEM.V

1 Comment

Admin

4 years ago

Hemostemix Inc is currently in a long term downtrend where the price is trading 16.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Hemostemix Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 18.5% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 60.1% to $-514K since the same quarter in the previous year.

Based on the above factors, Hemostemix Inc gets an overall score of 2/5.

Exchange	V
CurrencyCode	CAD
ISIN	CA4236943060
Sector	Healthcare
Industry	Biotechnology

Beta	-0.12
Market Cap	13M
PE Ratio	None
Target Price	0.96
Dividend Yield	None

ABOUT

Hemostemix Inc

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

HEM.V · Hemostemix Inc

-

Hemostemix Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Hemostemix Inc using a moving average strategy